Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

FTC Challenges Payments to Delay Generics

Deal to keep generic drug off the market is anti-competitive, regulators say

By Clay Dillow, Newser Staff

Posted Feb 3, 2009 9:25 AM CST

(Newser) – The Federal Trade Commission, pledging to oppose “pay-for-delay” agreements, filed suit against a brand-name testosterone-replacement drug manufacturer for paying three competitors to delay introductions of generic versions, the Washington Post reports. Nearly half of settlements between brand-name drug-makers and their generic counterparts in 2006... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

4 comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Miami Face-Eater Identified

Victim of Naked Face-Eater Fights for Life

Washington Post (Source Grid »)

California AG joins FTC in monopoly suit
Los Angeles Business Journal

Watson, Par caught up in 'pay-to-delay' scandal
Forbes

Glaxo to cut more than 6,000 as generic competition weighs heavy
BBC

Money • Crime & Courts • Health

pharmaceutical companies • FTC • generic drugs • monopoly • antitrust suit • pharmaceutical industry • Solvay Pharmaceuticals

More Newser Stories

Pfizer to Can 800 Researchers

Company must cut R&D spending ahead of Lipitor patent expiration

(NEWSER) - Pfizer will eliminate the jobs of up to 800 researchers in 2009, starting today, the Wall Street Journal reports. The pharmaceutical giant is attempting to cut costs ahead of a $30 billion reduction in revenue expected in 2011 when its patent on the popular cholesterol drug Lipitor expires. But the cuts signal a larger rethinking of pharmaceutical R&D. More»

US to Big Pharma: Disclose What You Pay Docs

New rules aim to increase transparency

(NEWSER) - Studies have found that when doctors accept payments from drug companies, it can influence their treatment decisions—so the Obama administration will soon require drug companies to disclose those payments. The New York Times reports that around 25% of doctors receive cash from drug companies for consulting, speaking engagements, and more; in addition, almost two-thirds accept staff lunches or dinners out. The new requirements, part of the new health care law, will ensure that such payments and gifts, even small ones, are disclosed on a website; drug companies will be subject to fines for any omissions. More»

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

(NEWSER) - Gilead Sciences announced today that it will license four AIDS and hepatitis B drugs to an international patent pool, allowing cheap, generic versions to be produced for sale in low-income countries. The AIDS drugs, which include tenofovir and emtricitabine, represent a major upgrade on the treatments currently available in those countries, the New York Times reports. The move makes Gilead the first major drug manufacturer to contribute to the Medicines Patent Pool. More»

US Prescription Drugs Tested on World's Poor

Drugs declared 'safe' on basis of unregulated trials abroad

(NEWSER) - Prescription drugs that are considered safe kill an estimated 200,000 Americans a year, and investigative reporters Donald L. Barlett and James B. Steele have exposed a massive loophole that could help explain why. Some 6,485 clinical trials were conducted abroad in 2008—more than 20 times as many as in 1990—and the FDA has been declaring drugs safe based on foreign trials that are almost completely free from regulation or oversight, a detailed investigation published in Vanity Fair finds. More»

Disgraced Doctors Land at Big Pharma

Hundreds of pitchmen found to have blemished records

(NEWSER) - Pharmaceutical companies say they hire highly respected doctors as their white-coat sales force, peddling their drugs to other physicians. But a Pro Publica investigation has discovered that hundreds of these pitchmen have been accused of professional misconduct, been disciplined by state boards, or lacked credentials. Medical board records in the 15 most populous states revealed that more than 250 had been sanctioned, another 40 given FDA warnings for research lapses, and 20 more hit with successful malpractice lawsuits. Some have even lost their licenses. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

FTC Challenges Payments to Delay Generics

Deal to keep generic drug off the market is anti-competitive, regulators say

pharmaceutical companies • FTC • generic drugs • monopoly • antitrust suit • pharmaceutical industry • Solvay Pharmaceuticals

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Pfizer to Can 800 Researchers

Company must cut R&D spending ahead of Lipitor patent expiration

US to Big Pharma: Disclose What You Pay Docs

New rules aim to increase transparency

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

US Prescription Drugs Tested on World's Poor

Drugs declared 'safe' on basis of unregulated trials abroad

Disgraced Doctors Land at Big Pharma

Hundreds of pitchmen found to have blemished records

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?